Business
Medical Marijuana, Inc. Subsidiary Kannaway® Celebrates Best Revenue Month in Company History for South Africa Division in March 2022
Medical Marijuana, Inc. Subsidiary Kannaway® Celebrates Best Revenue Month in Company History for South Africa Division in March 2022.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n SAN DIEGO, CA, April 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® achieved its largest revenue month in the company’s history in its South Africa division in March 2022. Africa’s cannabis industry is rapidly expanding, becoming one of the Company’s top international growth markets, and is projected to be a $7 billion market by 2023. Reach and Markets highlights that the South African cannabis/cannabidiol (CBD) market is expected to see a CAGR of 28.4% Between 2022 and 2026. “2022 has been a truly remarkable year for sales in South Africa so far,” said Medical Marijuana, Inc. CEO Blake Schroeder. “We’re excited about our very rapid growth in the market and look forward to continued growth not only in South Africa but also our expansion throughout the continent as cannabis becomes legally accepted and free access continues to be newly enabled.” To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/. About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was...